Tumor categories as described by the World Health Organization reflect, in part, a true genetic heterogeneity (e.g., translocations involving CRTC1 and CRTC3-MAML2 genes in mucoepidermoid carcinoma and MYB-NFIB fusion in adenoid cystic carcinoma).
Finally, genomic analyses identified a novel <i>NFIB</i>-<i>MTFR2</i> fusion in an ACC tumor and confirmed previously reported fusions (<i>NTRK3</i>-<i>ETV6</i> and <i>MYB</i>-<i>NFIB)</i><b>Conclusions:</b> Sequential MEC PDX models preserved key patient features and enabled the identification of genetic events putatively contributing to increases in both CSC proportion and intrinsic tumorigenicity, which mirrored the patient's clinical course.<i></i>.